Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
These drugs are approved to treat all six major genotypes of hepatitis C.
This from a real-world analysis of people treated for hep C in the United States.
A study compared treatment outcomes among those seen at standard intervals with those seen for just two clinic visits.
A real-world study of AbbVie’s hep C regimen Mavyret (glecaprevir/pibrentasvir) included people often excluded from clinical trials.
Nearly all those who have completed follow-up in an ongoing Italian study have been cured.
These two men both recently discovered that they had hepatitis C, each with a different story about their encounters with insurance.
A review of the major findings presented at the Annual Meeting of the American Association for the Study of Liver Diseases in San Francisco
Nearly all those treated in a recent trial were cured.
People without hep C received kidney, liver or heart transplants from HCV-positive donors and then were treated for the virus.
The study population included those with all hepatitis C genotypes—except genotype 3.
A recent analysis of two studies of AbbVie’s hepatitis C regimen showed good results in this population.
Hepatitis C patient is cured with Mavyret; she continues to share her treatment experience in part 2 of this interview with Connie Welch.
Hepatitis C patient is cured with Mavyret, one of the newest highly effective hepatitis C treatments out on the market.
With many hepatitis C treatments on the market today, patients may ask which hepatitis C treatment is right for me? What’s the difference?
The annual scientific meeting on liver health revealed exciting new findings concerning the battle against the hep C epidemic.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.